Keyword: Forbion Capital Partners
The financing comes months after NorthSea enrolled the first NASH patient in the trial of its structurally engineered fatty acid icosabutate.
The financing sets AM-Pharma up to advance in sepsis-associated acute kidney injury independently now Pfizer has turned down its option to buy.
The financing sets Sanifit up to take its lead drug through phase 3 while exploring its potential in other progressive vascular calcification disorders.
A new Atlas-incubated startup focused on rare forms of muscle diseases has got off a $50 million series A with experienced executives at the helm.
The agreement gives Novo the chance to add an anti-apoC3 antibody treatment for abnormal lipid levels to its pipeline.
The Forbion-led series B tees up Inflazome to trial its NLRP3 inflammasome inhibitors in several inflammatory diseases.
The Forbion-led series C round sets Omeicos up to run a phase 2 trial of its small molecule analogue of a natural omega-3 fatty acid metabolite.
The addition of €90 million since the first close in July means Forbion has pulled in almost twice as much money as it managed for its third fund.
Medical device and diagnostics startups were integral to Forbion’s first three funds but will receive only a fraction of the $316 million fourth fund.
The bumper first close of the fund follows a period in which Forbion has shown a knack for picking winners.